TFX - Teleflex
178.16
| Index: | S&P 500 | P/E: | 35.41 | EPS (ttm): | 5.03 | Insider Own: | 0.26% | Shs Outstand: | 46.44M | Perf Week: | -1.10% |
| Market Cap: | 8.43B | Forward P/E: | 11.73 | EPS next Y: | 15.19 | Insider Trans: | -2.13% | Shs Float: | 46.32M | Perf Month: | -4.95% |
| Income(ttm): | 237.44M | PEG: | 4.72 | EPS next Q: | 3.86 | Inst Own: | 98.52% | Short Float: | 1.07% | Perf Quarter: | -27.24% |
| Revenue(ttm): | 3.03B | P/S: | 2.79 | EPS this Y: | 3.45% | Inst Trans: | -2.16% | Short Ratio: | 1.17 | Perf Half Y: | -11.24% |
| Book/sh: | 96.50 | P/B: | 1.85 | EPS next Y: | 8.59% | ROA: | 3.18% | Short Interest: | 0.49M | Perf Year: | -28.05% |
| Cash/sh: | 5.14 | P/C: | 34.67 | EPS next 5Y: | 7.50% | ROE: | 5.41% | 52W Range: | 171.69 - 256.85 | Perf YTD: | -28.55% |
| Dividend Est.: | 1.36 (0.76%) | P/FCF: | 18.74 | EPS past 5Y: | 11.91% | ROI: | 3.80% | 52W High: | -30.64% | Beta: | 1.16 |
| Dividend TTM: | 1.36 (0.76%) | Quick Ratio: | 1.39 | Sales past 5Y: | 4.08% | Gross Margin: | 55.86% | 52W Low: | 3.77% | ATR (14): | 4.83 |
| Dividend Ex-Date: | Nov 15, 2024 | Current Ratio: | 2.42 | EPS Y/Y TTM: | -41.15% | Oper. Margin: | 18.08% | RSI (14): | 34.86 | Volatility: | 2.78% 2.42% |
| Employees: | 14500 | Debt/Eq: | 0.42 | Sales Y/Y TTM: | 2.27% | Profit Margin: | 7.85% | Recom: | 2.25 | Target Price: | 238.90 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.39 | EPS Q/Q: | -18.56% | Payout: | 18.05% | Rel Volume: | 3.18 | Prev Close: | 174.79 |
| Sales Surprise: | -0.56% | EPS Surprise: | 2.88% | Sales Q/Q: | 2.41% | Earnings: | Oct 31 BMO | Avg Volume: | 422.51K | Price: | 178.16 |
| SMA20: | -3.82% | SMA50: | -12.37% | SMA200: | -18.15% | Undervalued: 34.09% | Volume: | 1,344,363 | Change: | 1.93% | |
Graham Classic formula value: 106.14
(P/E=8 * 1g) Min value: 70.01
(current P/E * 2g) Max value: 227.69
Average value: 134.61
Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.